Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RAMIN SCHADLU

Allopathic & Osteopathic Physicians Ophthalmology

NPI
1962428276
CMS profile
224408
Location
PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$342.36

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $229.02 1
Food and Beverage $113.34 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Carl Zeiss Meditec, Inc. $229.02 1
Dutch Ophthalmic, USA $113.34 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RAMIN SCHADLU

NPI 1962428276 · CMS profile ID 224408

Allopathic & Osteopathic Physicians / Ophthalmology

PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1962428276?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RAMIN SCHADLU, NPI 1962428276, CMS profile ID 224408. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962428276?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). RAMIN SCHADLU, NPI 1962428276, CMS profile ID 224408. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962428276?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
RAMIN SCHADLU, NPI 1962428276, CMS profile ID 224408, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1962428276?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $342.36 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Dutch Ophthalmic, USA $113.3403/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698426861 CMS
Carl Zeiss Meditec, Inc. $229.0203/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693206363 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $342.36 2
PY2022 $94.38 3
PY2023 $74.11 2
PY2025 $104.40 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $147,287.84 62
PY2024 Principal investigator $73,667.87 28
PY2023 Principal investigator $227,079.95 47
PY2022 Principal investigator $415,702.86 97
PY2021 Principal investigator $591,398.19 100
PY2020 Principal investigator $245,197.99 33
PY2019 Principal investigator $146,195.66 17

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

100 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,199.10 12/23/2021 Non-covered Recipient Entity
DOCTRIALS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 793116479
Principal investigator 1 Genentech, Inc. $39,332.00 12/22/2021 Non-covered Recipient Entity
DOCTRIALS LLC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 835955189
Principal investigator 1 Hexal AG $9,742.87 12/22/2021 Non-covered Recipient Entity
DOCTRIALS LLC
CSOK583A12301 No dispute reported 06/30/2026 779780699
Principal investigator 1 Genentech, Inc. $1,833.25 12/20/2021 Non-covered Recipient Entity
DOCTRIALS LLC
PORT DELIVERY SYSTEM OF RANIBIZUMAB EXTENSION STUDY No dispute reported 06/30/2026 835955183
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,636.87 12/20/2021 Non-covered Recipient Entity
DOCTRIALS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 793116177
Principal investigator 1 Genentech, Inc. $6,546.96 12/15/2021 Non-covered Recipient Entity
DOCTRIALS LLC
PORT DELIVERY SYSTEM FOR RANIBIZUMAB No dispute reported 06/30/2026 835955171
Principal investigator 1 Genentech, Inc. $1,316.00 12/15/2021 Non-covered Recipient Entity
DOCTRIALS LLC
PORT DELIVERY SYSTEM OF RANIBIZUMAB EXTENSION STUDY No dispute reported 06/30/2026 835955177
Principal investigator 1 Genentech, Inc. $12,000.00 12/06/2021 Non-covered Recipient Entity
DOCTRIALS LLC
OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF FARICIMAB IN PATIENTS WITH NAMD No dispute reported 06/30/2026 835955165
Principal investigator 1 Genentech, Inc. $9,684.00 12/03/2021 Non-covered Recipient Entity
DOCTRIALS LLC
FARICIMAB DME LONG TERM EXTENSION RHONE X No dispute reported 06/30/2026 835955159
Principal investigator 1 Apellis Pharmaceuticals, Inc. $26.99 12/02/2021 Non-covered Recipient Entity
DOCTRIALS, LLC
Oaks No dispute reported 06/30/2026 821325167
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,749.90 12/02/2021 Non-covered Recipient Entity
DOCTRIALS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 793114791
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,044.00 12/02/2021 Non-covered Recipient Entity
DOCTRIALS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 793114793
Principal investigator 1 Genentech, Inc. $2,781.35 11/21/2021 Non-covered Recipient Entity
DOCTRIALS LLC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 835955153
Principal investigator 1 Roche TCRC, Inc. $8,445.60 11/19/2021 Non-covered Recipient Entity
DOCTRIALS, LLC
ORAL TREATMENT OF NPDR No dispute reported 06/30/2026 835955247
Principal investigator 1 Roche TCRC, Inc. $64.76 11/19/2021 Non-covered Recipient Entity
DOCTRIALS, LLC
ORAL TREATMENT OF NPDR No dispute reported 06/30/2026 835955253
Principal investigator 1 Grifols, S.A. $1,000.00 11/18/2021 Non-covered Recipient Entity
ARIZONA RETINA AND VITREOUS CONSULTANTS LLC
A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy CAPRI No dispute reported 06/30/2026 845837323
Principal investigator 1 Grifols, S.A. $500.00 11/18/2021 Non-covered Recipient Entity
ARIZONA RETINA AND VITREOUS CONSULTANTS LLC
A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy CAPRI No dispute reported 06/30/2026 845837409
Principal investigator 1 Grifols, S.A. $7,500.00 11/18/2021 Non-covered Recipient Entity
ARIZONA RETINA AND VITREOUS CONSULTANTS LLC
A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy CAPRI No dispute reported 06/30/2026 845837425
Principal investigator 1 Grifols, S.A. $1,500.00 11/18/2021 Non-covered Recipient Entity
ARIZONA RETINA AND VITREOUS CONSULTANTS LLC
A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy CAPRI No dispute reported 06/30/2026 845837523
Principal investigator 1 Grifols, S.A. $750.00 11/18/2021 Non-covered Recipient Entity
ARIZONA RETINA AND VITREOUS CONSULTANTS LLC
A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy CAPRI No dispute reported 06/30/2026 845837555
Principal investigator 1 Grifols, S.A. $2,000.00 11/18/2021 Non-covered Recipient Entity
ARIZONA RETINA AND VITREOUS CONSULTANTS LLC
A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy CAPRI No dispute reported 06/30/2026 845837557
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,517.40 11/08/2021 Non-covered Recipient Entity
DOCTRIALS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 793113351
Principal investigator 1 Genentech, Inc. $7,537.50 10/27/2021 Non-covered Recipient Entity
DOCTRIALS LLC
VA2 PHIII No dispute reported 06/30/2026 835955147
Principal investigator 1 Genentech, Inc. $50.62 10/21/2021 Non-covered Recipient Entity
DOCTRIALS LLC
PHASE 2 OF RO7171009 IN GA No dispute reported 06/30/2026 835954895
Principal investigator 1 Genentech, Inc. $8,000.00 10/12/2021 Non-covered Recipient Entity
DOCTRIALS LLC
BELVEDERE No dispute reported 06/30/2026 835954901
Principal investigator 1 Genentech, Inc. $2,391.00 10/11/2021 Non-covered Recipient Entity
DOCTRIALS LLC
PORT DELIVERY SYSTEM FOR RANIBIZUMAB No dispute reported 06/30/2026 835955141
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.68 10/07/2021 Non-covered Recipient Entity
DOCTRIALS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 793111291
Principal investigator 1 Genentech, Inc. $3,474.00 10/04/2021 Non-covered Recipient Entity
DOCTRIALS LLC
PORT DELIVERY SYSTEM OF RANIBIZUMAB EXTENSION STUDY No dispute reported 06/30/2026 835955129
Principal investigator 1 Genentech, Inc. $2,250.00 10/04/2021 Non-covered Recipient Entity
DOCTRIALS LLC
PORT DELIVERY SYSTEM FOR RANIBIZUMAB No dispute reported 06/30/2026 835955135
Principal investigator 1 Hexal AG $15,200.00 09/29/2021 Non-covered Recipient Entity
DOCTRIALS LLC
CSOK583A12301 No dispute reported 06/30/2026 779780677
Principal investigator 1 Genentech, Inc. $46,510.00 09/27/2021 Non-covered Recipient Entity
DOCTRIALS LLC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 835955123
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,500.00 09/23/2021 Non-covered Recipient Entity
DOCTRIALS LLC
A 12-MONTH, 2-ARM, RANDOMIZED, DOUBLE-MASKED, MULTICENTER PHASE III STUDY ASSESSING THE EFFICACY AND SAFETY OF BROLUCIZUMAB VS. AFLIBERCEPT IN PATIENTS WITH VISUAL IMPAIRMENT DUE TO DIABETIC MACULAR EDEMA (KINGFISHER) No dispute reported 06/30/2026 800629655
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $23,192.82 09/23/2021 Non-covered Recipient Entity
DOCTRIALS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 793110587
Principal investigator 1 Genentech, Inc. $2,661.50 09/03/2021 Non-covered Recipient Entity
DOCTRIALS LLC
VA2 PHIII No dispute reported 06/30/2026 835955117
Principal investigator 1 Grifols, S.A. $750.00 09/02/2021 Non-covered Recipient Entity
ARIZONA RETINA AND VITREOUS CONSULTANTS LLC
A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy CAPRI No dispute reported 06/30/2026 845837809
Principal investigator 1 Roche TCRC, Inc. $206.00 08/31/2021 Non-covered Recipient Entity
DOCTRIALS, LLC
ORAL TREATMENT OF NPDR No dispute reported 06/30/2026 835955243
Principal investigator 1 Genentech, Inc. $8,504.09 08/27/2021 Non-covered Recipient Entity
DOCTRIALS LLC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 835955105
Principal investigator 1 Genentech, Inc. $704.00 08/27/2021 Non-covered Recipient Entity
DOCTRIALS LLC
VA2 PHIII YOSEMITE No dispute reported 06/30/2026 835955111
Principal investigator 1 Genentech, Inc. $3,998.00 08/25/2021 Non-covered Recipient Entity
DOCTRIALS LLC
FARICIMAB DME LONG TERM EXTENSION RHONE X No dispute reported 06/30/2026 835955093
Principal investigator 1 Genentech, Inc. $2,037.00 08/25/2021 Non-covered Recipient Entity
DOCTRIALS LLC
PORT DELIVERY SYSTEM FOR RANIBIZUMAB No dispute reported 06/30/2026 835955099
Principal investigator 1 Grifols, S.A. $500.00 08/20/2021 Non-covered Recipient Entity
ARIZONA RETINA AND VITREOUS CONSULTANTS LLC
A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy CAPRI No dispute reported 06/30/2026 845837699
Principal investigator 1 Grifols, S.A. $1,000.00 08/19/2021 Non-covered Recipient Entity
ARIZONA RETINA AND VITREOUS CONSULTANTS LLC
A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy CAPRI No dispute reported 06/30/2026 845837683
Principal investigator 1 Grifols, S.A. $1,500.00 08/18/2021 Non-covered Recipient Entity
ARIZONA RETINA AND VITREOUS CONSULTANTS LLC
A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy CAPRI No dispute reported 06/30/2026 845837695
Principal investigator 1 Grifols, S.A. $2,000.00 08/17/2021 Non-covered Recipient Entity
ARIZONA RETINA AND VITREOUS CONSULTANTS LLC
A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy CAPRI No dispute reported 06/30/2026 845837697
Principal investigator 1 Grifols, S.A. $7,500.00 08/16/2021 Non-covered Recipient Entity
ARIZONA RETINA AND VITREOUS CONSULTANTS LLC
A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy CAPRI No dispute reported 06/30/2026 845837685
Principal investigator 1 Genentech, Inc. $12,060.00 08/13/2021 Non-covered Recipient Entity
DOCTRIALS LLC
VA2 PHIII No dispute reported 06/30/2026 835955087
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $86.73 08/05/2021 Non-covered Recipient Entity
DOCTRIALS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 793107527
Principal investigator 1 Genentech, Inc. $4,210.20 08/03/2021 Non-covered Recipient Entity
DOCTRIALS LLC
PHASE 2 OF RO7171009 IN GA No dispute reported 06/30/2026 835954889
Principal investigator 1 Roche TCRC, Inc. $10,267.20 07/31/2021 Non-covered Recipient Entity
DOCTRIALS, LLC
ORAL TREATMENT OF NPDR No dispute reported 06/30/2026 835955237
Principal investigator 1 Genentech, Inc. $11,135.65 07/28/2021 Non-covered Recipient Entity
DOCTRIALS LLC
VA2 PHIII YOSEMITE No dispute reported 06/30/2026 835955075
Principal investigator 1 Genentech, Inc. $670.90 07/28/2021 Non-covered Recipient Entity
DOCTRIALS LLC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 835955081
Principal investigator 1 Genentech, Inc. $1,618.00 07/26/2021 Non-covered Recipient Entity
DOCTRIALS LLC
VA2 PHIII YOSEMITE No dispute reported 06/30/2026 835955069
Principal investigator 1 Roche TCRC, Inc. $1,000.00 06/30/2021 Non-covered Recipient Entity
DOCTRIALS, LLC
ORAL TREATMENT OF NPDR No dispute reported 06/30/2026 835955231
Principal investigator 1 Genentech, Inc. $3,032.00 06/27/2021 Non-covered Recipient Entity
DOCTRIALS LLC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 835955057
Principal investigator 1 Genentech, Inc. $26,610.00 06/27/2021 Non-covered Recipient Entity
DOCTRIALS LLC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 835955063
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 06/24/2021 Non-covered Recipient Entity
DOCTRIALS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 793104755
Principal investigator 1 Genentech, Inc. $89.09 06/23/2021 Non-covered Recipient Entity
DOCTRIALS LLC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 835955051
Principal investigator 1 Genentech, Inc. $2,522.00 06/18/2021 Non-covered Recipient Entity
DOCTRIALS LLC
PORT DELIVERY SYSTEM OF RANIBIZUMAB EXTENSION STUDY No dispute reported 06/30/2026 835955045
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $401.92 06/01/2021 Non-covered Recipient Entity
DOCTRIALS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 793103387
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17,632.31 05/27/2021 Non-covered Recipient Entity
DOCTRIALS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 793103209
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,909.96 05/25/2021 Non-covered Recipient Entity
DOCTRIALS LLC
A 64-WEEK, PHASE 3B, MULTI-CENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF BROLUCIZUMAB 6MG COMPARED TO AFLIBERCEPT 2MG IN A TREAT TO CONTROL REGIMEN IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 800629661
Principal investigator 1 Genentech, Inc. $4,546.00 05/21/2021 Non-covered Recipient Entity
DOCTRIALS LLC
FARICIMAB DME LONG TERM EXTENSION RHONE X No dispute reported 06/30/2026 835955039
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,522.00 05/03/2021 Non-covered Recipient Entity
DOCTRIALS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 793101877
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $286.86 05/03/2021 Non-covered Recipient Entity
DOCTRIALS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 793101881
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $168.41 04/29/2021 Non-covered Recipient Entity
DOCTRIALS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 793101739
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.38 04/29/2021 Non-covered Recipient Entity
DOCTRIALS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 793101741
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,788.00 04/29/2021 Non-covered Recipient Entity
DOCTRIALS
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 793101743
Principal investigator 1 Genentech, Inc. $1,419.00 04/28/2021 Non-covered Recipient Entity
DOCTRIALS LLC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 835955027
Principal investigator 1 Genentech, Inc. $1,696.00 04/28/2021 Non-covered Recipient Entity
DOCTRIALS LLC
PORT DELIVERY SYSTEM FOR RANIBIZUMAB No dispute reported 06/30/2026 835955033
Principal investigator 1 Roche TCRC, Inc. $32,512.50 04/26/2021 Non-covered Recipient Entity
DOCTRIALS, LLC
ORAL TREATMENT OF NPDR No dispute reported 06/30/2026 835955225
Principal investigator 1 Genentech, Inc. $6,272.00 04/21/2021 Non-covered Recipient Entity
DOCTRIALS LLC
PORT DELIVERY SYSTEM OF RANIZIBUMAB EXTENSION STUDY No dispute reported 06/30/2026 835955015
Principal investigator 1 Genentech, Inc. $2,277.50 04/21/2021 Non-covered Recipient Entity
DOCTRIALS LLC
VA2 PHIII No dispute reported 06/30/2026 835955021
Principal investigator 1 Genentech, Inc. $9,335.00 04/12/2021 Non-covered Recipient Entity
DOCTRIALS LLC
VA2 PHIII No dispute reported 06/30/2026 835955009
Principal investigator 1 Genentech, Inc. $19.36 04/08/2021 Non-covered Recipient Entity
DOCTRIALS LLC
PHASE 2 OF RO7171009 IN GA No dispute reported 06/30/2026 835954877
Principal investigator 1 Genentech, Inc. $41.45 04/08/2021 Non-covered Recipient Entity
DOCTRIALS LLC
PHASE 2 OF RO7171009 IN GA No dispute reported 06/30/2026 835954883
Principal investigator 1 Genentech, Inc. $4,106.00 04/07/2021 Non-covered Recipient Entity
DOCTRIALS LLC
VA2 PHIII YOSEMITE No dispute reported 06/30/2026 835954997
Principal investigator 1 Genentech, Inc. $2,152.96 04/07/2021 Non-covered Recipient Entity
DOCTRIALS LLC
PORT DELIVERY SYSTEM FOR RANIBIZUMAB No dispute reported 06/30/2026 835955003
Principal investigator 1 Genentech, Inc. $7,000.00 03/24/2021 Non-covered Recipient Entity
DOCTRIALS LLC
FARICIMAB DME LONG TERM EXTENSION RHONE X No dispute reported 06/30/2026 835954991
Principal investigator 1 Genentech, Inc. $13,122.05 03/22/2021 Non-covered Recipient Entity
DOCTRIALS LLC
VA2 PHIII No dispute reported 06/30/2026 835954985
Principal investigator 1 Genentech, Inc. $4,036.00 03/18/2021 Non-covered Recipient Entity
DOCTRIALS LLC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 835954967
Principal investigator 1 Genentech, Inc. $9,104.00 03/18/2021 Non-covered Recipient Entity
DOCTRIALS LLC
PORT DELIVERY SYSTEM FOR RANIBIZUMAB No dispute reported 06/30/2026 835954973
Principal investigator 1 Genentech, Inc. $3,032.00 03/18/2021 Non-covered Recipient Entity
DOCTRIALS LLC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 835954979
Principal investigator 1 Genentech, Inc. $3,972.00 03/15/2021 Non-covered Recipient Entity
DOCTRIALS LLC
PORT DELIVERY SYSTEM OF RANIZIBUMAB EXTENSION STUDY No dispute reported 06/30/2026 835954961
Principal investigator 1 Roche TCRC, Inc. $9,756.50 03/11/2021 Non-covered Recipient Entity
DOCTRIALS, LLC
ORAL TREATMENT OF NPDR No dispute reported 06/30/2026 835955219
Principal investigator 1 Genentech, Inc. $147.00 03/08/2021 Non-covered Recipient Entity
DOCTRIALS LLC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 835954955
Principal investigator 1 Genentech, Inc. $7,682.40 02/25/2021 Non-covered Recipient Entity
DOCTRIALS LLC
PHASE 2 OF RO7171009 IN GA No dispute reported 06/30/2026 835954871
Principal investigator 1 Genentech, Inc. $32.85 02/22/2021 Non-covered Recipient Entity
DOCTRIALS LLC
FARICIMAB DME LONG TERM EXTENSION RHONE X No dispute reported 06/30/2026 835954949
Principal investigator 1 Genentech, Inc. $534.64 02/19/2021 Non-covered Recipient Entity
DOCTRIALS LLC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 835954937
Principal investigator 1 Genentech, Inc. $6,230.00 02/19/2021 Non-covered Recipient Entity
DOCTRIALS LLC
FARICIMAB DME LONG TERM EXTENSION RHONE X No dispute reported 06/30/2026 835954943
Principal investigator 1 Roche TCRC, Inc. $381.22 02/19/2021 Non-covered Recipient Entity
DOCTRIALS, LLC
ORAL TREATMENT OF NPDR No dispute reported 06/30/2026 835955207
Principal investigator 1 Roche TCRC, Inc. $500.00 02/19/2021 Non-covered Recipient Entity
DOCTRIALS, LLC
ORAL TREATMENT OF NPDR No dispute reported 06/30/2026 835955213
Principal investigator 1 Genentech, Inc. $50.89 02/12/2021 Non-covered Recipient Entity
DOCTRIALS LLC
PORT DELIVERY SYSTEM FOR RANIBIZUMAB No dispute reported 06/30/2026 835954931
Principal investigator 1 Genentech, Inc. $5,000.00 01/26/2021 Non-covered Recipient Entity
DOCTRIALS LLC
PHASE 2 OF RO7171009 IN GA No dispute reported 06/30/2026 835954859
Principal investigator 1 Genentech, Inc. $500.00 01/26/2021 Non-covered Recipient Entity
DOCTRIALS LLC
PHASE 2 OF RO7171009 IN GA No dispute reported 06/30/2026 835954865
Principal investigator 1 Genentech, Inc. $500.00 01/25/2021 Non-covered Recipient Entity
DOCTRIALS LLC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 835954925
Principal investigator 1 Roche TCRC, Inc. $7,406.10 01/21/2021 Non-covered Recipient Entity
DOCTRIALS, LLC
ORAL TREATMENT OF NPDR No dispute reported 06/30/2026 835955201
Principal investigator 1 Genentech, Inc. $12,290.00 01/15/2021 Non-covered Recipient Entity
DOCTRIALS LLC
VA2 PHIII No dispute reported 06/30/2026 835954919
Principal investigator 1 Genentech, Inc. $8,330.90 01/08/2021 Non-covered Recipient Entity
DOCTRIALS LLC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 835954913
Principal investigator 1 Roche TCRC, Inc. $12,500.00 01/08/2021 Non-covered Recipient Entity
DOCTRIALS, LLC
ORAL TREATMENT OF NPDR No dispute reported 06/30/2026 835955195
Principal investigator 1 Genentech, Inc. $8,606.00 01/06/2021 Non-covered Recipient Entity
DOCTRIALS LLC
VA2 PHIII YOSEMITE No dispute reported 06/30/2026 835954907